Calidi Biotherapeutics, Inc. (CLDI)
NYSEAMERICAN: CLDI · Real-Time Price · USD
2.150
0.00 (0.00%)
Nov 22, 2024, 3:52 PM EST - Market closed
Calidi Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
41
Market Cap
41.34M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | - | - | - |
Dec 31, 2022 | 45.00K | -404.00K | -89.98% |
Dec 31, 2021 | 449.00K | - | - |
Dec 31, 2020 | - | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionCLDI News
- 8 days ago - Calidi Biotherapeutics Announces Closing of $7.5 Million Public Offering of Common Stock - GlobeNewsWire
- 9 days ago - Calidi Biotherapeutics Announces Pricing of $7.5 Million Public Offering of Common Stock - GlobeNewsWire
- 10 days ago - Calidi Biotherapeutics Announces Proposed Public Offering - GlobeNewsWire
- 11 days ago - Calidi Biotherapeutics Reports Third Quarter 2024 Operating and Financial Results - GlobeNewsWire
- 4 weeks ago - Nexalin Technology and Calidi Biotherapeutics Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Accesswire
- 4 weeks ago - Calidi Biotherapeutics to Present Data Supporting RTNova at Upcoming Scientific Conferences - GlobeNewsWire
- 4 weeks ago - Calidi Biotherapeutics Announces Pricing of $2 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewsWire
- 5 weeks ago - NYSE American to Commence Delisting Proceedings with Respect to the Warrants of Calidi Biotherapeutics, Inc. (CLDI WS) - GlobeNewsWire